Results 181 to 190 of about 169,027 (313)

Recent progress on nanotechnologies for enhancing blood‐brain barrier permeability

Smart Molecules, EarlyView.
In this review, we summarize innovative strategies for harnessing the power of nanotechnology to enhance blood‐brain barrier permeability, a key challenge for central nervous system (CNS) drug delivery. We overview structural innovation of nanocarriers, improvements in targeting strategies, and nanotechnology‐enhanced brain imaging.
Qibin Liu, Zhuoqian Chen, Anthony Guiseppi‐Elie, Fanling Meng, Liang Luo   +4 more
wiley   +1 more source

Disease Clearance in Ulcerative Colitis: A Narrative Review

United European Gastroenterology Journal, EarlyView.
ABSTRACT Ulcerative colitis (UC) is a chronic relapsing disease with significant associated risks such as colectomy, hospitalization, or colorectal cancer. A treat‐to‐target approach that mitigates disease activity and progression from an early stage is needed.
Silvio Danese, Laurent Peyrin‐Biroulet, Vipul Jairath, Ferdinando D'Amico, Shashi Adsul, Christian Agboton, Fernando Magro   +6 more
wiley   +1 more source

Nectin4‐targeted molecular imaging in solid tumors: Current status and future perspectives

VIEW, EarlyView.
In this review, we provide a concise overview of the mechanisms by which Nectin4 contributes to the pathogenesis of various malignancies and detail the classes of Nectin4‐targeted molecular probes. We then delve into the significant advancements in Nectin4‐targeted molecular imaging techniques, encompassing both nuclear medicine and optical imaging ...
Yongshun Liu, Wenpeng Huang, Jingwei Zhou, Rachel J. Saladin, Youlan Lei, Weibo Cai, Lei Kang   +6 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Transgenesis and humanization of murine antibodies.

, 2009
International audienceThe properties of monoclonal antibodies explain why they are such a successful class of therapeutic molecules. However, pionneered initial antibodies were of murine origin and triggered an immune response which limited the ...
Cogné, Michel, Duchez, Sophie, Pascal, Virginie   +2 more
core   +1 more source

An Effective Prophylactic and Therapeutic Protection Against Botulinum Type A Intoxication in Mice and Rabbits Using a Humanized Monoclonal Antibody. [PDF]

Toxins (Basel)
Yu CH, Song YJ, Song DH, Joe HE, Kim CH, Yun H, Kim NY, Sim E, Jeong ST, Hur GH.   +9 more
europepmc   +1 more source

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. In the difficult‐to‐treat BP or if standard therapies are contraindicated, the use of biologics may be also considered although there is no strong evidence supporting their use.
Gianluca Avallone, Carlo Alberto Maronese, Martina Zussino, Simona Muratori, Silvia Mariel Ferrucci, Pietro Quaglino, Elisabetta Manni, Marco Romanelli, Clara De Simone, Caterina Foti, Luigi Gargiulo, Vincenzo Maione, Piergiacomo Calzavara‐Pinton, Federico Bardazzi, Bianca Maria Piraccini, Emiliano Antiga, Giulia Rech, Riccardo Balestri, Pamela Vezzoli, Paolo Sena, Maria Esposito, Maria Concetta Fargnoli, Davide Termini, Luca Valtellini, Rosanna Rita Satta, Camilla Vassallo, Alessia Provini, Giovanni Di Zenzo, Anna Campanati, Marzia Caproni, Emanuele Cozzani, Simone Ribero, Angelo Valerio Marzano, DUO—DUpilumab and Omalizumab in Bullous Pemphigoid Study Group, Armando Pisapia, Giovanni Genovese, Federica Gelato, Luca Mastorino, Cristian Fidanzi, Luca Rapparini, Domenico Simeoli, Elena Marra, Gennaro Marco Falco, Paolo Romita, Riccardo Viola, Mauro Grandolfo, Luciano Ibba, Luisa Sarno, Roberto Maglie, Valentina Ruffo di Calabria, Aurora Parodi   +50 more
wiley   +1 more source

The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools. [PDF]

Eur Heart J Cardiovasc Pharmacother
Lüscher TF.
europepmc   +1 more source

B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. [PDF]

J Immunother Precis Oncol
Phipps M, Falchook GS.
europepmc   +1 more source

Physical Exercise Decreases Complement‐Mediated Synaptic Loss and Protects Against Cognitive Impairment by Inhibiting Microglial Tmem9‐ATP6V0D1 in Alzheimer's Disease

Aging Cell, EarlyView.
In a 5xFAD mouse model, we observed that physical exercise reduced the levels of microglial Tmem9, thereby inhibiting complement activation through its interaction with ATP6V0D1. Consequently, this attenuation of complement‐dependent synaptic loss led to significant improvements in both emotional and cognitive impairments. ABSTRACT Physical exercise is
Shiyin Li, Mingyue Li, Ge Li, Lili Li, Xiaofeng Yang, Zejie Zuo, Liying Zhang, Xiquan Hu, Xiaofei He   +8 more
wiley   +1 more source